RHB-102 (Bekinda®) (24 mg), an investigational drug, is in development in the UK for the management of chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV, respectively) in adults. Our partner, Hyloris Pharmaceuticals, which holds the worldwide rights excluding North America to develop and commercialize RHB-102, is advancing development for oncology support in the UK with a planned Marketing Authorization Application (MAA).
RHB-102 is a proprietary bimodal immediate and extended-release, once-daily oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist. RHB-102 is intended to provide patients with relief from nausea and vomiting symptoms for 24 hours with a single oral tablet.